Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

被引：3

作者：

Handunnetti, Sasanka ^{[1
,2
,3
]}

Anderson, Mary Ann ^{[1
,2
,4
]}

Roberts, Andrew W. ^{[1
,2
,3
,4
]}

Davids, Matthew S. ^{[5
]}

Ma, Shuo ^{[6
]}

Boyer, Michelle ^{[7
]}

Arzt, Jennifer ^{[8
]}

Al Masud, Abdullah ^{[8
]}

Popovic, Relja ^{[8
]}

Jacobson, Amanda ^{[8
]}

Kim, Su Y. ^{[8
]}

Seymour, John F. ^{[1
,2
,4
]}

机构：

[1] Peter MacCallum Canc Ctr, Clin Haematol Dept, 305 Grattan St, Melbourne, Vic, Australia

[2] Royal Melbourne Hosp, 305 Grattan St, Melbourne, Vic, Australia

[3] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia

[4] Walter & Eliza Hall Inst Med Res, Div Blood Cells & Blood Canc, Parkville, Vic, Australia

[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[7] F Hoffmann La Roche Ltd, Welwyn Garden City, England

[8] AbbVie Inc, N Chicago, IL USA

来源：

EJHAEM | 2021年 / 2卷 / 02期

关键词：

chronic lymphocytic leukemia; relapsed/refractory; rituximab; small lymphocytic lymphoma; venetoclax; CLL; OBINUTUZUMAB; DIAGNOSIS; BCL2;

D O I：

10.1002/jha2.177

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12-175 [NCT01328626]; M13-365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax monotherapy could receive added rituximab. Ten patients were evaluated (M12-175, n = 8; M13-365, n = 2), and five (50%) responded again upon addition of rituximab, including three complete and two partial responses. Responses were ongoing after 5-10 months of follow-up. Addition of rituximab was well tolerated. These findings indicate potential clinical benefit with rituximab added to venetoclax post-progression in some patients with R/R CLL.

引用

页码：266 / 271

页数：6

共 17 条

[1] Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax [J].

Anderson, Mary Ann ;

Tam, Constantine ;

Lew, Thomas E. ;

Juneja, Surender ;

Juneja, Manu ;

Westerman, David ;

Wall, Meaghan ;

Lade, Stephen ;

Gorelik, Alexandra ;

Huang, David C. S. ;

Seymour, John F. ;

Roberts, Andrew W. .

BLOOD, 2017, 129 (25) :3362-3370

[2] Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia [J].

Blombery, Piers ;

Anderson, Mary Ann ;

Gong, Jia-nan ;

Thijssen, Rachel ;

Birkinshaw, Richard W. ;

Thompson, Ella R. ;

Teh, Charis E. ;

Nguyen, Tamia ;

Xu, Zhen ;

Flensburg, Christoffer ;

Lew, Thomas E. ;

Majewski, Ian J. ;

Gray, Daniel H. D. ;

Westerman, David A. ;

Tam, Constantine S. ;

Seymour, John F. ;

Czabotar, Peter E. ;

Huang, David C. S. ;

Roberts, Andrew W. .

CANCER DISCOVERY, 2019, 9 (03) :342-353

[3] Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era [J].

Butler, L. A. ;

Tam, C. S. ;

Seymour, J. F. .

BLOOD REVIEWS, 2017, 31 (05) :318-327

[4] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions [J].

Fischer, K. ;

Al-Sawaf, O. ;

Bahlo, J. ;

Fink, A. -M. ;

Tandon, M. ;

Dixon, M. ;

Robrecht, S. ;

Warburton, S. ;

Humphrey, K. ;

Samoylova, O. ;

Liberati, A. M. ;

Pinilla-Ibarz, J. ;

Opat, S. ;

Sivcheva, L. ;

Du, K. Le ;

Fogliatto, L. M. ;

Niemann, C. U. ;

Weinkove, R. ;

Robinson, S. ;

Kipps, T. J. ;

Boettcher, S. ;

Tausch, E. ;

Humerickhouse, R. ;

Eichhorst, B. ;

Wendtner, C. -M. ;

Langerak, A. W. ;

Kreuzer, K. -A. ;

Ritgen, M. ;

Goede, V. ;

Stilgenbauer, S. ;

Mobasher, M. ;

Hallek, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) :2225-2236

[5] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions [J].

Goede, Valentin ;

Fischer, Kirsten ;

Busch, Raymonde ;

Engelke, Anja ;

Eichhorst, Barbara ;

Wendtner, Clemens M. ;

Chagorova, Tatiana ;

de la Serna, Javier ;

Dilhuydy, Marie-Sarah ;

Illmer, Thomas ;

Opat, Stephen ;

Owen, Carolyn J. ;

Samoylova, Olga ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Doehner, Hartmut ;

Langerak, Anton W. ;

Ritgen, Matthias ;

Kneba, Michael ;

Asikanius, Elina ;

Humphrey, Kathryn ;

Wenger, Michael ;

Hallek, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) :1101-1110

[6] Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [J].

Hallek, Michael ;

Cheson, Bruce D. ;

Catovsky, Daniel ;

Caligaris-Cappio, Federico ;

Dighiero, Guillaume ;

Doehner, Hartmut ;

Hillmen, Peter ;

Keating, Michael J. ;

Montserrat, Emili ;

Rai, Kanti R. ;

Kipps, Thomas J. .

BLOOD, 2008, 111 (12) :5446-5456

[7] Ibrutinib and Venetoclax for First-Line Treatment of CLL [J].

Jain, Nitin ;

Keating, Michael ;

Thompson, Philip ;

Ferrajoli, Alessandra ;

Burger, Jan ;

Borthakur, Gautam ;

Takahashi, Koichi ;

Estrov, Zeev ;

Fowler, Nathan ;

Kadia, Tapan ;

Konopleva, Marina ;

Alvarado, Yesid ;

Yilmaz, Musa ;

DiNardo, Courtney ;

Bose, Prithviraj ;

Ohanian, Maro ;

Pemmaraju, Naveen ;

Jabbour, Elias ;

Sasaki, Koji ;

Kanagal-Shamanna, Rashmi ;

Patel, Keyur ;

Jorgensen, Jeffrey ;

Garg, Naveen ;

Wang, Xuemei ;

Sondermann, Katrina ;

Cruz, Nichole ;

Wei, Chongjuan ;

Ayala, Ana ;

Plunkett, William ;

Kantarjian, Hagop ;

Gandhi, Varsha ;

Wierda, William .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22) :2095-2103

[8] Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx) [J].

Kater, Arnon P. ;

Kipps, Thomas J. ;

Eichhorst, Barbara ;

Hillmen, Peter ;

D'Rozario, James ;

Owen, Carolyn ;

Assouline, Sarit E. ;

Lamanna, Nicole ;

Robak, Tadeusz J. ;

de la Serna, Javier ;

Jaeger, Ulrich ;

Cartron, Guillaume ;

Montillo, Marco ;

Mellink, Clemens ;

Chyla, Brenda J. ;

Wilson, Cameron ;

Wu, Jenny ;

Jiang, Yanwen ;

Lefebure, Marcus ;

Boyer, Michelle ;

Seymour, John F. .

BLOOD, 2020, 136

[9] BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax [J].

Lin, Victor S. ;

Lew, Thomas E. ;

Handunnetti, Sasanka M. ;

Blombery, Piers ;

Nguyen, Tamia ;

Westerman, David A. ;

Kuss, Bryone J. ;

Tam, Constantine S. ;

Roberts, Andrew W. ;

Seymour, John F. ;

Anderson, Mary Ann .

BLOOD, 2020, 135 (25) :2266-2270

[10] Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy [J].

Mato, Anthony R. ;

Roeker, Lindsey E. ;

Jacobs, Ryan ;

Hill, Brian T. ;

Lamanna, Nicole ;

Brander, Danielle ;

Shadman, Mazyar ;

Ujjani, Chaitra S. ;

Yazdy, Maryam Sarraf ;

Perini, Guilherme Fleury ;

Pinilla-Ibarz, Javier A. ;

Barrientos, Jacqueline ;

Skarbnik, Alan P. ;

Torka, Pallawi ;

Pu, Jeffrey J. ;

Pagel, John M. ;

Gohil, Satyen ;

Fakhri, Bita ;

Choi, Michael ;

Coombs, Catherine C. ;

Rhodes, Joanna ;

Barr, Paul M. ;

Portell, Craig A. ;

Parry, Helen ;

Garcia, Christine A. ;

Whitaker, Kate J. ;

Winter, Allison M. ;

Sitlinger, Andrea ;

Khajavian, Sirin ;

Grajales-Cruz, Ariel F. ;

Isaac, Krista M. ;

Shah, Pratik ;

Akhtar, Othman S. ;

Pocock, Rachael ;

Lam, Kentson ;

Voorhees, Timothy J. ;

Schuster, Stephen J. ;

Rodgers, Thomas D. ;

Fox, Christopher P. ;

Martinez-Calle, Nicolas ;

Munir, Talha ;

Bhavsar, Erica B. ;

Bailey, Neil ;

Lee, Jason C. ;

Weissbrot, Hanna B. ;

Nabhan, Chadi ;

Goodfriend, Julie M. ;

King, Amber C. ;

Zelenetz, Andrew D. ;

Dorsey, Colleen .

CLINICAL CANCER RESEARCH, 2020, 26 (14) :3589-3596

← 1 2 →